SER
Serina Therapeutics·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
Bullish Abandoned Baby
Shooting Star
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SER
Serina Therapeutics, Inc.
A biotechnology company that developing therapeutics for human aging and regeneration
Life Science Tools and Services
--
11/29/2018
American Stock Exchange
12
12-31
Common stock
601 Genome Way, Suite 2001, Huntsville, Alabama 35806
--
Serina Therapeutics, Inc., incorporated in Delaware in January 2017, is a subsidiary of BioTime. The company is a biotechnology company focused on the development and commercialization of novel therapies for human aging. Their mission is to apply comprehensive experience in the basic biological processes of human aging to a wide range of relevant medical conditions. The company believes that the demand for therapies to address this condition is rising in line with the demographic shift of aging in the United States and many other industrialized countries.
Company Financials
EPS
SER has released its 2025 Q3 earnings. EPS was reported at -0.45, versus the expected -0.53, beating expectations. The chart below visualizes how SER has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
